In international health practice and health economics, drug availability and pricing are considered one of the key factors in citizens' living standards and social protection. High prices of medicines First of all, they hit the socially vulnerable sections of the population - those with chronic diseases, pensioners and low-income families. When essential medicines become unaffordable � unaffordable, it not only increases the financial burden on citizens, but also directly undermines the efficiency of the public health system. In Armenia, this problem has been deepening for years because of the current policy Absorption mechanisms did not provide the necessary competition. In a detailed study, we see the obvious disparity in the prices of drugs of the same name sold in Armenia and neighboring Georgia. In particular, cardiovascular, diabetes, etc The prices of a number of drugs used against gastrointestinal, as well as antibiotics and respiratory diseases in Armenia are several times higher than the prices of the Georgian market. Thus, "Metformin Denk" for diabetes in Armenia costs 4,260 drams, while in Georgia it is sold for 1,590 drams, and the average price of "Omeprazole" in our country reaches 5,360 drams, compared to 1,140 drams in the neighboring country. The press has already written that within the framework of the settlement of this problem, Narek Karapetyan, the head of the "Strong Armenia" faction of the National Assembly, had a meeting with the European Medicines and Healthcare Supervision Agency during his working visit to Strasbourg. with the Director of the Clean Center (EDQM) Petra Dyor. The focus of the discussion was increasing access to European-made quality medicines in Armenia and expanding the range of registered medicines, which will allow to reduce prices and bring them to the level of Georgia, which has more than 1.3 million citizens. giving the opportunity to save hundreds of thousands of drams annually. Another important step followed this process. Narek Karapetyan, faction secretary Tigran Abrahamyan and MP Harutyun Harutyunyan met with Ambassador Vasilis Maragos, head of the European Union delegation in Armenia, discussing the recent primary legislative initiatives and institutional cooperation in the field of health care. Thus, serious, systematic institutional work is being carried out in the direction of drug market reform. Prepare the question Through in-depth discussions with international partners and harmonization of European standards, which does not allow any loopholes so that artificial monopolies and interest groups formed in the pharmaceutical market can interfere. � to legislative changes. Putting the issue under discussion in a broad spectrum creates an opportunity for the Armenian citizen to be the final winner this time, receiving quality and significantly more affordable medicine.